by Robert Minicucci | Apr 22, 2020 | Uncategorized
Oncology clinical trials have been disrupted as hospitals dedicate more resources to care for COVID-19 patients. While the scope delays and suspensions are hard to assess, halting these trials can create devastating effects for patients in need of experimental...
by Robert Minicucci | Feb 12, 2020 | Uncategorized
Concerns & Barriers Around Real-World Data Adoption At Inteliquet, we partner with Life Sciences and help reduce the barriers and time involved in clinical research. We recently conducted a survey to examine real-world data (RWD) adoption. Since the adoption is...
by Robert Minicucci | Jan 28, 2020 | Uncategorized
For those of us in healthcare, the year begins with the JP Morgan Healthcare Conference. 2020 was no exception, so we wanted to know how Marie E. Lamont, a veteran of this conference, makes the most of her time. Here’s what she said: This year, I had the...
by Robert Minicucci | Oct 12, 2019 | Uncategorized
“Too much cost. Too much time. Too much uncertainty,” were themes heard over and over at 2019’s DPharm: Disruptive Innovations Conference in Boston. The two-day gathering highlights the promises and challenges of bringing innovation to drug development, so...
by Robert Minicucci | Jul 11, 2019 | Uncategorized
Patient forecasting needs innovation since traditional methods, such as using past experience and estimates from investigators, consistently fail sponsors and CROs. In fact, data show that: Nearly 80% of clinical trials don’t meet enrollment timelines.*Up to half of...
